Could a cancer drug tame tough seizures? tiny trial begins

NCT ID NCT07095933

Recruiting now Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether everolimus, a drug usually used for cancer, can help control seizures in people with drug-resistant focal epilepsy. Only 5 adults aged 18-60 will take the drug during seizure events for 12 weeks. The goal is to see if seizure frequency drops and if the drug is safe enough for a larger trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus
What this could lead to: If it works, this could point toward a new medication option for people with hard-to-control epilepsy, taken only during seizure events.
What could go wrong: This is a very early pilot study with only 5 people, so results may not apply broadly. The drug may not reduce seizures or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG RESISTANT EPILEPSY

Contacts and locations

Locations

Xuanwu Hospital, Beijing
RECRUITING

Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.